title: Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.
authors.forename: Peter
authors.initials: P
authors.lastname: Hillmen
mesh_terms: D000814:Aniline Compounds / Q000008:administration & dosage* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013449:Sulfonamides / Q000008:administration & dosage* / Q000494:pharmacology*; D013792:Thalidomide / Q000031:analogs & derivatives*; D013873:Thionucleotides / Q000493:pharmacokinetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
chemical_list: D000814:Aniline Compounds; D000970:Antineoplastic Agents; D007155:Immunologic Factors; D016376:Oligonucleotides, Antisense; D019253:Proto-Oncogene Proteins c-bcl-2; D013449:Sulfonamides; D013873:Thionucleotides; D016159:Tumor Suppressor Protein p53; D013792:Thalidomide; C528561:navitoclax